Rheumatoid Arthritis Market

Rheumatoid Arthritis Market Outlook (2024 to 2034)

The global rheumatoid arthritis market size is estimated at a valuation of US$ 857.5 million in 2024 and is projected to reach US$ 1.56 billion by the end of 2034, expanding at a CAGR of 6.2% over the next ten years.

Demand for rheumatoid arthritis medicines has spiraled upward in recent years as people’s understanding of their health is rising. Rheumatoid arthritis is a chronic inflammatory disorder that predominantly affects the joints. This condition can damage various body systems such as the skin, eyes, lungs, heart, and blood vessels, as the immune system attacks healthy tissues, weakening the individual and increasing the risk of mortality.

In recent years, a growing focus on health and fitness has led people to recognize the importance of health. This trend has directly influenced arthritis drug manufacturers, contributing to rheumatoid arthritis market growth.

• According to the Centers for Disease Control and Prevention, the onset of rheumatoid arthritis is two to three times more likely in females than in males. This analysis has provided valuable insights to suppliers, prompting them to prioritize female patients and improve drug components to enhance their presence in the market.

Adults aged 60 to 65 are susceptible to this disease. By prioritizing adult females, suppliers are capitalizing on this demographic, thus contributing to the overall expansion of the rheumatoid arthritis market. The most common medications for RA fall into five categories: non-steroidal anti-inflammatory drugs (NSAIDs), steroids, disease-modifying anti-rheumatic drugs (DMARDs), biologics, and Janus kinase inhibitors. Suppliers ensure a consistent supply of these medications to maintain market dominance and outperform competitors.

Another strategy employed by suppliers is collaboration with hospitals, clinics, and healthcare providers to identify areas for improvement in the supply chain. This collaborative approach results in effective and efficient growth in supply throughout the year.

• The Japanese market is projected to expand at a CAGR of 6.9% from 2024 to 2034.

Report Attributes	Details
Rheumatoid arthritis Market Size (2024E)	US$ 857.5 Million
Forecasted Market Value (2034F)	US$ 1.56 Billion
Global Market Growth Rate (2024 to 2034)	6.2% CAGR
Canada Market Growth Rate (2024 to 2034)	5.2% CAGR
China Market Value (2034F)	US$ 173 Million
North America Market Share (2024E)	39.7%
East Asia Market Share (2034F)	15%
Key Companies Profiled	AbbVie Inc Johnson & Johnson Innovative Medicine Amgen Inc. Pfizer Inc. Novartis AG Sanofi SA Bristol Myers Squibb Celgene Corporation

Which Healthcare Trends are Driving Adoption of Tests for Rheumatoid Arthritis?

“Rising Prevalence of Autoimmune Diseases”

Increasing incidence of autoimmune disorders, such as rheumatoid arthritis, has prompted the need for quick diagnostic test solutions that would cut down on the time and effort needed for sample testing. Consequently, the commercialization of innovative quick diagnostic test kits possessing elevated specificity and sensitivity is the primary focus of makers of autoimmune disease test kits.

Due to the low specificity of current diagnostic techniques, doctors are increasingly adopting the practice of using several tests (such as rheumatoid factor and antinuclear antibody tests) to diagnose rheumatoid arthritis. The effectiveness of rheumatoid arthritis therapy is tracked using a combination of testing techniques. Therefore, the demand for rheumatoid arthritis diagnostic test kits is projected to rise.

“Growing Government Assistance to Provide Innovative and Affordable Medications”

One of the main factors projected to fuel the expansion of the rheumatoid arthritis market size during the forecast period is the increased investments by governments in the development of innovative and affordable medications for rheumatoid arthritis surveillance and treatment. To lessen their burden in monitoring and treating rheumatoid arthritis, government agencies are funding research and development projects.

Controlling the global spread of rheumatoid arthritis is largely dependent on government assistance for diagnosis and surveillance of the disease. Over the projection period, increasing spending on monitoring epidemiology and surveillance of rheumatoid arthritis is projected to contribute to an increase in the number of cases.

Rheumatoid arthritis does not currently have a viable therapy. However, as an off-label therapy, doctors typically give anti-inflammatory medications to people with rheumatoid arthritis, which helps lessen joint inflammation. Global demand for rheumatoid arthritis diagnosis test kits and treatment efficacy monitoring test kits has surged as a result of doctors prescribing more medications off-label. Due to their high sensitivity and specificity, the antinuclear antibody (ANA) and anti-cyclic citrullinated peptide (anti-CCP) test segments are predicted to lead the market.

What is Affecting the Profit Margins of Rheumatoid Arthritis Testing Providers?

“Limited Reliability and Accuracy of RA Test Kits”

One major obstacle limiting the development of rheumatoid arthritis test kits at the moment is their inadequate sensitivity and specificity in comparison to other test kits on the market. The specificity and sensitivity of conventional test techniques, such as erythrocyte sedimentation rate (ESR) and rheumatoid factor (RF) testing, are restricted. Test findings from cutting-edge diagnostic test kits, such as antinuclear antibody (ANA) and anti-cyclic citrullinated peptide (anti-CCP) assays, have excellent sensitivity and specificity. Because of their high cost, increasing the uptake of diagnostic tests is a considerable problem.

Specificity and sensitivity of conventional testing for the diagnosis of rheumatoid arthritis are restricted. As a result, test results have a maximum false positive rate. An elevated occurrence of false positive outcomes could undermine the reliability of rheumatoid arthritis diagnosis test kits, potentially impeding market expansion. Widespread utilization of traditional rheumatoid arthritis testing methods, such as the RF test and ESR test, has led to an increase in the positivity ratio in rheumatoid arthritis testing, encompassing both true and false positives.

Due to the difficulty in determining the underlying etiology of rheumatoid arthritis, test kits for the condition are now confronting issues with specificity and sensitivity. Combination testing has been used by doctors to identify and track the development of rheumatoid arthritis. As a result, the price of combination test kits for diagnosis is rising.

Country-wise Evaluation

The South Korean market is projected to expand at a CAGR of 6% from 2024 to 2034.

Why is the United States a Commercially Viable for Rheumatoid Arthritis Test Kit Suppliers?

“Government Initiatives and Educational Campaigns to Raise Awareness of Rheumatoid Arthritis”

Attribute	United States
Market Value (2024E)	US$ 275 Million
Growth Rate (2024 to 2034)	5.6% CAGR
Projected Value (2034F)	US$ 474 Million

The United States government is taking proactive steps to address the increasing incidence of rheumatoid arthritis to educate citizens about the disease and facilitate its treatment. For suppliers, this presents a prime opportunity to establish dominance in the United States market and significantly expand their presence.

• According to 2021 data from the Centers for Disease Control and Prevention (CDC), arthritis affects 24% of adult Americans, totaling 58.5 million individuals. This condition severely impacts individuals' ability to work and incurs an annual cost of US$ 303.5 billion to the country, covering missed income and medical expenses. Rheumatoid arthritis, lupus, gout, and osteoarthritis are among the most prevalent forms of arthritis, with 57.3% of working-age individuals (aged 18 to 64) in the country affected.

What Makes China an Investment-worthy Market for Rheumatoid Arthritis Testing Providers?

“Increasing Prevalence of Rheumatoid Arthritis among Elderly Population”

Attribute	China
Market Value (2024E)	US$ 94 Million
Growth Rate (2024 to 2034)	6.4% CAGR
Projected Value (2034F)	US$ 173 Million

The market in China is being mainly driven by an increase in the elderly population that is more susceptible to ailments such as rheumatoid arthritis.

• The Asian Development Bank states that by 2050, one in four individuals in Asia Pacific is projected to be over 60. Between 2010 and 2050, the number of senior people (those over 60) in the region is expected to increase three times, approaching 1.3 billion. This creates a lucrative market that allows the providers to maximize their earnings and reap their profits from this commercially fertile market.

Category-wise Insights

More suppliers are reaching out to diverse end users to provide their medications, including hospitals, diagnostic laboratories, private clinics, public healthcare facilities, and ambulatory surgical centers. Among these, the private laboratories segment is projected to expand at a CAGR of 4.6% from 2024 to 2034.

Why are Serology Tests Extensively Adopted for Detection of Rheumatoid Arthritis?

“Accuracy of Serology Tests in Detecting Antibodies in Blood Samples”

Attribute	Serology
Segment Value (2024E)	US$ 647.7 Million
Growth Rate (2024 to 2034)	6.7% CAGR
Projected Value (2034F)	US$ 1.23 Billion

People suffering from rheumatoid arthritis prefer serology over other available tests, as the former accurately detects antibodies or other harmful agents in blood samples. Serology is also preferred due to its cost-effectiveness, contributing to its growing popularity as a testing method. Immunoassays represent the most commonly utilized serological tests. Point-of-care (POC) tests are employed in diagnostic procedures for detecting antigens, antibodies, and nucleic acids.

Which End User Accounts for a Significant Market Share?

“Preference for Diagnostic Laboratories Driven by Reliable Results”

Attribute	Diagnostic Laboratories
Segment Value (2024E)	US$ 270 Million
Growth Rate (2024 to 2034)	8.2% CAGR
Projected Value (2034F)	US$ 592.4 Million

When individuals undergo testing for rheumatoid arthritis, they typically undergo a series of tests to determine the specific symptoms present in the body. These diagnostic procedures predominantly occur in diagnostic laboratories, making them the preferred choice for reliable and trustworthy test results.

Competitive Rivalry

Key players in the rheumatoid arthritis market aim to reach a worldwide consumer base by utilizing their wide distribution network to provide their products at every stage of the supply chain. Manufacturers are acquiring businesses specializing in rheumatoid arthritis-related products to meet the growing demand for rheumatoid arthritis diagnosis solutions.

Important producers are also focusing on cutting-edge research, such as biomarker-based rheumatoid arthritis diagnostic techniques, which are projected to open up new business prospects for producers of rheumatoid arthritis test kits, contributing to the evolving rheumatoid arthritis market trends.

• A Biocon Ltd. subsidiary, Biocon Biologics Ltd., announced in July 2023 that HULIO (adalimumab-flip) injectable, a biosimilar of Humira (adalimumab), was now available in the United States for the treatment of rheumatoid arthritis.

Key Segments of Rheumatoid Arthritis Market Research

• By Test Type :

  • Serology Tests
    • Erythrocyte Sedimentation Rheumatoid Arthritis (ESR)
    • Rheumatoid Factor (RF)
    • Anti-cyclic Citrullinated Peptide (anti-CCP)
    • Antinuclear Antibody (ANA)
    • Uric Acid
  • Monitoring Rheumatoid Arthritis Treatment Efficiency Tests
    • Salicylate Level Count
    • Muscle Enzyme Tests
    • Creatinine Tests

• By End User :

  • Hospitals
  • Diagnostic Laboratories
    • Private Laboratories
    • Public Laboratories
  • Ambulatory Surgical Centers

• By Region :

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Middle East & Africa